Bradley Duffy

Array ( [id] => 12158845 [patent_doc_number] => 20180030111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'FC MUTANTS WITH MODIFIED FUNCTIONAL ACTIVITY' [patent_app_type] => utility [patent_app_number] => 15/554022 [patent_app_country] => US [patent_app_date] => 2016-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16425 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15554022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17539907 [patent_doc_number] => 11305011 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Kappa myeloma antigen chimeric antigen receptors and uses thereof [patent_app_type] => utility [patent_app_number] => 15/568271 [patent_app_country] => US [patent_app_date] => 2016-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 23 [patent_no_of_words] => 14542 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15568271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11102175 [patent_doc_number] => 20160299145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'Methods and Kits for Detecting Prostate Cancer Biomarkers' [patent_app_type] => utility [patent_app_number] => 15/132821 [patent_app_country] => US [patent_app_date] => 2016-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 44470 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15132821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17000589 [patent_doc_number] => 11079393 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels [patent_app_type] => utility [patent_app_number] => 15/131804 [patent_app_country] => US [patent_app_date] => 2016-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 38 [patent_no_of_words] => 14842 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 259 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15131804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13916705 [patent_doc_number] => 10202460 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-12 [patent_title] => CD37-binding molecules and immunoconjugates thereof [patent_app_type] => utility [patent_app_number] => 15/130667 [patent_app_country] => US [patent_app_date] => 2016-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 39359 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15130667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414504 [patent_doc_number] => 10822380 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Disruption of the WAVE3 protein complex for suppression of invasion and metastasis [patent_app_type] => utility [patent_app_number] => 15/565229 [patent_app_country] => US [patent_app_date] => 2016-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 70 [patent_no_of_words] => 17505 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15565229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16924087 [patent_doc_number] => 11045543 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => EGFR-directed car therapy for glioblastoma [patent_app_type] => utility [patent_app_number] => 15/564166 [patent_app_country] => US [patent_app_date] => 2016-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 28 [patent_no_of_words] => 26360 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15564166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11122054 [patent_doc_number] => 20160319026 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/091468 [patent_app_country] => US [patent_app_date] => 2016-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 84453 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15091468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15052289 [patent_doc_number] => 10456420 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-29 [patent_title] => Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 15/529848 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 12107 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15529848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12580713 [patent_doc_number] => 20180085400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => ANTI-MICA ANTIGEN BINDING FRAGMENTS, FUSION MOLECULES, CELLS WHICH EXPRESS AND METHODS OF USING [patent_app_type] => utility [patent_app_number] => 15/561748 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20721 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11002560 [patent_doc_number] => 20160199509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'Cancer Treatment Comprising Therapeutics That Bind to Phosphatidylserine' [patent_app_type] => utility [patent_app_number] => 15/079700 [patent_app_country] => US [patent_app_date] => 2016-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 70548 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15079700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219237 [patent_doc_number] => 20180057595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'Anti-MET Antibodies and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 15/558306 [patent_app_country] => US [patent_app_date] => 2016-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 123555 [patent_no_of_claims] => 203 [patent_no_of_ind_claims] => 58 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15558306 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129272 [patent_doc_number] => 20160326247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'BIOLOGICAL PRODUCTS' [patent_app_type] => utility [patent_app_number] => 15/069078 [patent_app_country] => US [patent_app_date] => 2016-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 9402 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15069078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10988905 [patent_doc_number] => 20160185850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF ALPHA' [patent_app_type] => utility [patent_app_number] => 15/064067 [patent_app_country] => US [patent_app_date] => 2016-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 17799 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15064067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185480 [patent_doc_number] => 20180044416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'Polymeric Fc proteins and methods of screening to alter their functional characteristics' [patent_app_type] => utility [patent_app_number] => 15/554478 [patent_app_country] => US [patent_app_date] => 2016-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 89 [patent_figures_cnt] => 89 [patent_no_of_words] => 29272 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 28 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15554478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407189 [patent_doc_number] => 11248058 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Chimeric antigen receptors and uses thereof [patent_app_type] => utility [patent_app_number] => 15/552071 [patent_app_country] => US [patent_app_date] => 2016-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 65 [patent_no_of_words] => 33595 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15552071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12607242 [patent_doc_number] => 20180094244 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 15/551284 [patent_app_country] => US [patent_app_date] => 2016-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15551284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13154053 [patent_doc_number] => 10093739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => Covalent diabodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/046000 [patent_app_country] => US [patent_app_date] => 2016-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 28 [patent_no_of_words] => 64343 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 409 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15046000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13154051 [patent_doc_number] => 10093738 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => Covalent diabodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/040774 [patent_app_country] => US [patent_app_date] => 2016-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 63 [patent_no_of_words] => 85039 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 314 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15040774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12837457 [patent_doc_number] => 20180170992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 [patent_app_type] => utility [patent_app_number] => 15/545950 [patent_app_country] => US [patent_app_date] => 2016-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15545950 [rel_patent_id] =>[rel_patent_doc_number] =>)